Pulmonary Hypertension Therapy

Pulmonary hypertension therapy focuses on alleviating elevated pulmonary arterial pressures, improving right heart function, and enhancing exercise tolerance in patients with this progressive condition. Pulmonary hypertension can arise from diverse causes, including left heart disease, chronic lung disorders, chronic thromboembolic events, and idiopathic forms. Management strategies are tailored to the underlying etiology and disease severity, often requiring a combination of pharmacological and supportive interventions.

Vasodilator therapies, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, form the core of pharmacologic treatment, working to reduce pulmonary vascular resistance and improve cardiac output. Diuretics are used judiciously to manage fluid overload, while oxygen therapy addresses hypoxemia and reduces pulmonary vasoconstriction. In selected patients, anticoagulation may be prescribed, particularly when thromboembolic mechanisms are involved. Advanced interventions, such as atrial septostomy or lung transplantation, are considered for refractory cases where medical therapy alone is insufficient.

Regular monitoring of hemodynamics, exercise capacity, and right ventricular function is essential to guide therapy adjustments. Patient education regarding symptom recognition, adherence to medication, and lifestyle modifications—including structured exercise programs—supports functional improvement. Emerging research continues to explore novel molecular targets, gene therapies, and precision medicine approaches that may further optimize pulmonary hypertension therapy. By combining evidence-based pharmacological strategies with individualized monitoring and supportive care, management aims to stabilize disease progression, enhance functional capacity, and reduce the risk of complications related to elevated pulmonary pressures.